Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 6

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude...

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh...

February 2026 Psychedelic Bill Round-up

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

Colorado’s Ibogaine Bill Could Be a Landmark — If It Respects...

Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape

Load more

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©